ClinicalTrials.gg
Active, not recruitingNCT06653153Updated Oct 7, 2026

A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

A Phase 3 interventional study of Remternetug and Placebo in Alzheimer's Disease, sponsored by Eli Lilly and Company. Active, not recruiting at 262 sites in 10 countries. Open to participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,400
Allocation
Randomized
Ages
55 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 99 studies in Alzheimer Disease by Eli Lilly and Company — 13 open to participants now, 19 under way, 8 of them phase 3. Alzheimer Disease · Eli Lilly and Company.

Planned enrollment
10th of 95
1,400 · median 95
Started
2024
with 4 others
Phase 3
24 of 99
3 open now
Primary completion
2029-04
later than 13 of 18 live
Registered
88th of 99
by date

Among the 99 studies in Alzheimer Disease by Eli Lilly and Company, this one is the 10th largest by planned enrollment of the 95 interventional ones that give a count, is one of 5 that started in 2024, is one of 24 in phase 3, reaches primary completion later than 13 of the 18 other live ones, and was the 88th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

13 of the 99 studies in Alzheimer Disease by Eli Lilly and Company are open now, in 11 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Alzheimer Disease by Eli Lilly and Company, or all of them as a file.
02

Study summary

The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo.

Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participation to receive open-label remternetug in an extension period.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

04

Who can participate

Ages eligible
55 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a phosphorylated tau (P-tau) result consistent with the presence of amyloid pathology.
  • Have a reliable study partner and backup study partner familiar with overall function and behavior, such as day-to-day activities and cognitive abilities.
  • Have adequate literacy, vision, and hearing for neuropsychological testing at screening.
  • Have a Mini Mental Status Exam () score consistent with no to minimal cognitive impairment.
  • Have a Functional Activities Questionnaire (FAQ) score consistent with no to minimal functional impairment.
  • If currently receiving medications as symptomatic treatment for AD, dose has been stable for at least 30 days before screening.

Exclusion criteria

Exclusion Criteria:

  • Have dementia or significant other neurological disease that can affect cognition.
  • Have current serious or unstable illnesses that in the investigator's opinion, could interfere with the analyses of the study.
  • Have a history of cancer that, in the investigator's opinion, has a high risk of recurrence.
  • Have a history of multiple or severe drug allergies, or reactions.
  • Have a clinically important laboratory test result or other abnormality as determined by investigator, prior to randomization, that could be detrimental to the participant or could compromise the study.
  • Have any for magnetic resonance imaging (MRI).
  • Have a centrally read MRI that does not meets study entry criteria.

Prior or Current Therapies

  • Have ever had prior treatment with a passive anti-amyloid immunotherapy.
  • Have received active immunization against Aβ in any other study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,400 participants (estimated)

Study arms

  • Experimental
    Remternetug

    Remternetug administered subcutaneously (SC).

    Drug: Remternetug

  • Placebo comparator
    Placebo

    Placebo administered SC.

    Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY3372993

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Time to Clinically Meaningful Progression as Measured by Clinical Dementia Rate Scale (CDR)

    Time to clinically meaningful progression as measured by CDR. CDR is a clinician-rated scale that provides an overall assessment of the participant's stage and degree of impairment across the continuum of early Alzheimer's Disease (AD).

    Time frame: Baseline to Time to Event up to Week 255

Secondary outcomes

  1. Change from Baseline in Clinical Dementia Rate Box Score (SB)

    Change from baseline in Clinical Dementia Rate Box Score (SB) scores range from 0 to 18, with higher scores indicative of more impairment.

    Time frame: Baseline, Week 255

  2. Change from Baseline in Montreal Cognitive Assessment (MoCA)

    Change from baseline in Montreal Cognitive Assessment (MoCA). Total MoCA score is 0 to 30, with lower scores indicating greater level of impairment.

    Time frame: Baseline, Week 255

  3. Change from Baseline in the Category Fluency - Language, Executive Function, Semantic Memory

    Change from baseline in the Category Fluency - Language, Executive Function, Semantic Memory. The total score reflects the sum of correct responses generated across all categories presented, with higher values indicating better performance.

    Time frame: Baseline, Week 255

  4. Change from Baseline in the Continuous Paired Associate Learning (CPAL)

    Change from baseline in Continuous Paired Associate Learning (CPAL) - Visual episodic memory.

    Time frame: Baseline, Week 255

  5. Change from Baseline in International Shopping List Test (ISLT) - Verbal Episodic Mem

    Change from baseline in the International Shopping List Test (ISLT) - verbal episodic memory.

    Time frame: Baseline, Week 255

  6. Change from Baseline in International Daily Symbol Substitution Test-Medicines (iDSSTm) - Complex Attention Memory

    Change from baseline in the International Daily Symbol Substitution Test-Medicines (iDSSTm) - complex attention memory.

    Time frame: Baseline, Week 255

  7. Change from Baseline in Cognitive Function Index (CFI)

    Change from baseline in the Cognitive Function Index (CFI).

    Time frame: Baseline, Week 255

  8. Change from Baseline in Mild Behavioral Impairment Checklist (MBI-C)

    Change from baseline in the Mild Behavioral Impairment Checklist (MBI-C) The MBI-C total score range is 0 to 102, with higher scores indicating greater impairment.

    Time frame: Baseline, Week 255

  9. Change from Baseline in Alzheimer's Disease Cooperative Study (ADCS) Activities of Daily Living - Prevention Instrument (ADCS-ADL-PI)

    Change from baseline in the Activities of Daily Living - Prevention Instrument total scores range from 0 to 54, with higher scores indicating better performance.

    Time frame: Baseline, Week 255

  10. Pharmacokinetics: Serum Concentrations of Remternetug

    PK: serum concentration of remternetug.

    Time frame: Baseline through Week 255

  11. Number of Participants with Treatment Emergent Anti-Drug Antibodies (TE-ADAs)

    Number of participants with treatment emergent anti-drug antibodies (TE-ADAs).

    Time frame: Baseline through Week 255

07

Study locations

262 sites

Showing the first 100 of 262 sites across 10 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Apr 2029, 54 months after the start.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's planned 54 months is above that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2024
First posted
Oct 22, 2024
StartActual
Oct 24, 2024
Primary completionEst.
Apr 2029
CompletionEst.
Oct 2030
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
1 update, last Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06653153
Responsible party
Sponsor
First posted
Oct 22, 2024
Start date
Oct 24, 2024
Primary completion
Apr 2029 (estimated)
Completion
Oct 2030 (estimated)
Last update
Oct 7, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remternetug

Start the discussion